Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. - Wikidata - wikimedia - TriplyDB

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

http://www.wikidata.org/entity/Q33935859

about

Anti-vascular endothelial growth factor for diabetic macular oedema Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials Clinical Trials in Branch Retinal Vein Occlusion Anti-VEGF Therapy and the Retina: An Update Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy Current perspectives on ranibizumab An Endovascular Cannulation Needle with an Internal Wire for the Fragmentation of Thrombi in Retinal Vein Occlusion EFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.RETINAL BLOOD FLOW AFTER INTRAVITREAL BEVACIZUMAB IS A PREDICTIVE FACTOR FOR OUTCOMES OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION.Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.Evaluating the impact of vitreomacular adhesion on anti-VEGF therapy for retinal vein occlusion using machine learning Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases Treatment of macular edema due to retinal vein occlusions.Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40 Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review.Antiangiogenic therapy for ischemic retinopathies.Direct photocoagulation to leakage points to treat chronic macular edema associated with branch retinal vein occlusion: a pilot study Comparison of the efficacy of intravitreal triamcinolone acetonide for cystoid macular edema with versus without serous retinal detachment in branch retinal vein occlusion: influence on macular sensitivity and morphology.Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.Critical appraisal of ranibizumab in the treatment of diabetic macular edema.Branch retinal vein occlusion: treatment modalities: an update of the literature.Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion.The ABCs of RVO: a review of retinal venous occlusion.Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment.Pharmacotherapy for treatment of retinal vein occlusion.The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications.Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment.Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.

P2860

Q24193083-95A20A5F-2A42-433F-A8A3-22B7F74C5231 Q24201821-436B36E4-2128-467B-AD98-29D97BF01411 Q26750459-102367D4-DE8E-4217-AD0F-2D6B49D2F933 Q26767092-50C44213-7EBE-4158-88F7-217C2FFD0F83 Q26784605-EE606948-506A-4B09-99E7-68CF18F8697B Q26799492-982A73C2-0E24-4BD2-99D5-D8E1A5D91D29 Q26849299-7FF6DCE4-722D-4F5B-A7F9-6F718C3FE467 Q28082383-8CC7A641-78CD-408F-B410-07350ACBBB55 Q30372587-0F0401ED-60EC-4C2C-930D-2BC5682B1A3D Q30490419-C8462C5C-A51A-489F-A87B-D494DDD65982 Q30490830-AC256AFF-392A-45E9-A119-321141ABE1E6 Q31076710-D1D9F0DF-7740-470A-BCB4-59252E23DBD1 Q33648485-2D799CF9-2B88-49BC-9163-F9D81779057B Q33774284-4C1C5CED-2C7A-4E47-8965-16864BC8C91D Q33795991-FB839BB1-4E73-4495-89E1-56AB8DF2145B Q33828254-98C84D19-CBD2-4350-93C3-DACB65F93932 Q33840787-313E1D1B-A794-47F9-8ED6-318259CDE0FD Q33918085-27669D21-92F3-4C17-800F-46DBECFA5577 Q33996055-F8F3750E-35A8-480C-9C89-11411BFA683B Q34088274-9BC1B1FB-FC27-444B-BF20-2B6439C76E75 Q34139793-F11812E9-7D3B-4BBC-A567-69714022275F Q34206455-B4DA80F8-3A0F-4615-B7B0-66AC6700011F Q34249087-5C2214DD-C1AC-43A4-AEDD-92F206EC41B2 Q34295974-E3FFF758-A5C2-443C-B974-3AE73C4E572A Q34352584-8490E396-F042-444E-81D2-A386FBD17F35 Q34372914-569A7F25-75C3-49D6-89EF-244F2897B7B8 Q34708262-B1D524E9-F5F5-44D5-9A0F-57C4B0F80B48 Q34803171-4B876F41-86E3-42CA-B674-292C24C672AD Q35028773-63B73CA9-E371-420C-AFA6-9AB011758866 Q35036495-592D73A3-3BDD-4CD7-A6E1-D62C20B6A1CB Q35038286-C80E7760-7491-42A8-A011-AAAB1070ACDF Q35047634-7B844E17-D064-4050-9F2F-C038D4293F55 Q35135745-36F26A67-F07E-4F8F-B2FE-DC04E865DF67 Q35191520-FB4A5291-B4CB-4E85-B234-349887388907 Q35209724-ED836416-540C-42F6-9550-61AEB53F42AF Q35238074-0904BDC9-AF5E-48C3-A37F-46C6A07CCB53 Q35238943-034ACD5E-0353-4D04-86C9-BDE553068085 Q35269542-7FA691D5-D2AF-4F0F-AA6D-7679629556C7 Q35405601-846D9DF8-9667-4F13-8EA3-67DA18E310D6 Q35655005-5BC878DE-8581-4606-B42A-ACD896EE8AB4

P2860

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

http://www.wikidata.org/entity/Q33935859

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Sustained benefits from ranibi ...... outcomes of a phase III study.

@ast

Sustained benefits from ranibi ...... outcomes of a phase III study.

@en

type

label

Sustained benefits from ranibi ...... outcomes of a phase III study.

@ast

Sustained benefits from ranibi ...... outcomes of a phase III study.

@en

prefLabel

Sustained benefits from ranibi ...... outcomes of a phase III study.

@ast

Sustained benefits from ranibi ...... outcomes of a phase III study.

@en

P1433

Q33935859-E6110C07-ECAE-4932-8279-B7B299FBE260

P1476

Q33935859-00F11C6C-590D-4A35-B44B-BE364BDF78CB

P2093

Q33935859-0598F8B5-5A20-440F-8A2F-95402D160DF3

Q33935859-0AE6C295-17C5-4F0F-A2CA-8B003068D581

Q33935859-107A1E36-7248-4B47-86B0-4E62C83E7526

Q33935859-2BC7B02F-68B8-4268-AE34-E29FDB2D9624

Q33935859-7A4BFB14-2415-474D-9A03-DFCFDC23C2BC

Q33935859-8D959020-0F4B-450C-AE93-6151F23441FE

Q33935859-A9320C88-77AE-4E22-A51D-22A3D8EB73A2

Q33935859-DAB20CF4-E8A1-4EA5-976F-FDC68D32E39F

Q33935859-FB019AF5-6243-4CFD-849F-FF448082C7BC

P304

Q33935859-2C4EF07C-4948-40CC-8A7F-BFB13C66B79F

P31

Q33935859-3F9AC2D1-0971-420F-8F31-5694AB2D50D0

P356

Q33935859-8ED430DD-69B5-465A-8B4E-39CFD5952404

P433

Q33935859-8B06C4BE-43CF-4F31-AD7A-DE0DCEE8FA00

P478

Q33935859-5A65F9E0-4D6A-4AD9-B145-5C773274411E

P577

Q33935859-F5676090-C4CA-4F62-95E6-03F327178833

P698

Q33935859-136826D2-A997-4CEF-A20B-80F589D3D044

P356

J.OPHTHA.2011.02.022

P1433

P1476

Sustained benefits from ranibi ...... outcomes of a phase III study.

@en

P2093

Allen C Ho

http://www.w3.org/2001/XMLSchema#string

Anthony P Adamis

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

Namrata Saroj

http://www.w3.org/2001/XMLSchema#string

Peter A Campochiaro

http://www.w3.org/2001/XMLSchema#string

Robert B Bhisitkul

http://www.w3.org/2001/XMLSchema#string

Roman G Rubio

http://www.w3.org/2001/XMLSchema#string

Sarah Gray

http://www.w3.org/2001/XMLSchema#string

Wendy Yee Murahashi

http://www.w3.org/2001/XMLSchema#string

P304

1594-1602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2011.02.022

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21684606

http://www.w3.org/2001/XMLSchema#string